Skip to main content

Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner

  • 2015-07-28
  • PLOS ONE 10(7)
    • D. Šrůtková
    • M. Schwarzer
    • T. Hudcovic
    • Z. Zákostelská
    • V. Dráb
    • A. Španová
    • B. Rittich
    • H. Kozakova
    • I. Schabussova

Abstract

Background: Reduced microbial diversity has been associated with inflammatory bowel disease (IBD) and probiotic bacteria have been proposed for its prevention and/or treatment. Nevertheless, comparative studies of strains of the same subspecies for specific health benefits are scarce. Here we compared two Bifidobacterium longum ssp. longum strains for their capacity to prevent experimental colitis.

Methods: Immunomodulatory properties of nine probiotic bifidobacteria were assessed by stimulation of murine splenocytes. The immune responses to B. longum ssp. longum CCM 7952 (Bl 7952) and CCDM 372 (Bl 372) were further characterized by stimulation of bone marrow-derived dendritic cell, HEK293/TLR2 or HEK293/NOD2 cells. A mouse model of dextran sulphate sodium (DSS)-induced colitis was used to compare their beneficial effects in vivo.

Results: The nine bifidobacteria exhibited strain-specific abilities to induce cytokine production. Bl 372 induced higher levels of both pro- and anti-inflammatory cytokines in spleen and dendritic cell cultures compared to Bl 7952. Both strains engaged TLR2 and contain ligands for NOD2. In a mouse model of DSS-induced colitis, Bl 7952, but not Bl 372, reduced clinical symptoms and preserved expression of tight junction proteins. Importantly, Bl 7952 improved intestinal barrier function as demonstrated by reduced FITC-dextran levels in serum.

Conclusions: We have shown that Bl 7952, but not Bl 372, protected mice from the development of experimental colitis. Our data suggest that although some immunomodulatory properties might be widespread among the genus Bifidobacterium, others may be rare and characteristic only for a specific strain. Therefore, careful selection might be crucial in providing beneficial outcome in clinical trials with probiotics in IBD.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium lactis/longumImproved Intestinal Barrier FunctionBeneficial
Large
Bifidobacterium lactis/longumReduced Clinical Symptoms of ColitisBeneficial
Large
Bifidobacterium longum B1-05Improved Epithelial Barrier FunctionBeneficial
Large
Bifidobacterium longum B1-05Reduced Colitis-Related MortalityBeneficial
Large
Bifidobacterium longum Rosell-175Improved Intestinal Barrier FunctionBeneficial
Large
Bifidobacterium longum Rosell-175Prevention of ColitisBeneficial
Large
Bifidobacterium longum subsp. longumImproved Epithelial Barrier FunctionBeneficial
Large
Bifidobacterium longum subsp. longumReduced Colitis SymptomsBeneficial
Large
Bifidobacterium longum subsp. longum 35624Improved Intestinal Barrier FunctionBeneficial
Large
Bifidobacterium longum subsp. longum 35624Reduced Colitis SymptomsBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.